How should thrombocytosis be evaluated and managed?

Evaluation and Management of Thrombocytosis

Begin by determining if the thrombocytosis is primary (clonal) or secondary (reactive), as this fundamentally changes management—secondary thrombocytosis requires treating the underlying cause while primary thrombocytosis (essential thrombocythemia) requires risk-stratified cytoreductive therapy and antiplatelet agents to prevent thrombotic complications.

Initial Diagnostic Approach

Clinical Assessment for Secondary Causes

Immediately evaluate for these specific secondary causes, as their presence strongly suggests reactive thrombocytosis 1:

• Active malignancy (solid tumors or lymphoproliferative disorders) 2, 1
• Chronic inflammatory disease (connective tissue disease, infection) 2, 1
• Iron deficiency anemia (check ferritin) 2, 1
• Prior splenectomy 2, 1
• Recent surgery 3

Laboratory Evaluation

Order these specific tests to differentiate primary from secondary thrombocytosis 1, 3:

• Complete blood count with differential: Higher hemoglobin, MCV, RDW, and MPV suggest essential thrombocythemia; higher WBC and neutrophils suggest secondary thrombocytosis 1
• Ferritin level: Iron deficiency is a common cause of secondary thrombocytosis 2, 1
• Inflammatory markers (CRP, ESR) to identify underlying inflammation 3
• Peripheral blood smear to assess cell morphology 3

Molecular Testing Indications

Proceed with molecular testing (JAK2V617F, CALR, MPL mutations) only if secondary causes are excluded or if clinical features suggest essential thrombocythemia 1, 4:

• History of arterial thrombosis (strongly predictive of ET) 1
• Absence of malignancy, inflammation, splenectomy, or iron deficiency 1
• Sustained platelet count ≥450 × 10⁹/L without clear reactive cause 2

The yield of molecular testing is 52.4%, with 92.1% being JAK2, CALR, or MPL mutations 1. Avoid costly molecular testing in patients with clear secondary causes 1.

Diagnosis of Essential Thrombocythemia

All four WHO criteria must be met 2:

1. Sustained platelet count ≥450 × 10⁹/L 2
2. Bone marrow biopsy showing megakaryocytic proliferation with enlarged, mature megakaryocytes with deeply lobulated nuclei, without significant granulocytic or erythroid proliferation 2
3. Exclusion of other myeloid neoplasms: No polycythemia vera (normal hemoglobin/hematocrit after iron repletion if deficient), no primary myelofibrosis (no significant reticulin/collagen fibrosis), no CML (no BCR-ABL), no MDS (no dysplasia) 2
4. Demonstration of JAK2V617F or other clonal marker, OR exclusion of reactive causes if no clonal marker found 2

Common pitfall: The presence of a reactive condition does not exclude ET if the first three criteria are met 2.

Management of Essential Thrombocythemia

Risk Stratification for Thrombosis

High-risk features requiring cytoreductive therapy 5, 4:

• Age >60 years or history of thrombosis (arterial or venous, including splanchnic vein thrombosis) 5
• Platelet count ≥1,500 × 10⁹/L (extreme thrombocytosis) 5
• Cardiovascular risk factors (smoking, hypertension, diabetes) 3

Treatment Strategy

For high-risk patients 5:

• Hydroxyurea as first-line cytoreductive therapy to maintain platelet count <400 × 10⁹/L 5
• Low-dose aspirin (unless contraindicated by bleeding history) 5
• Address all cardiovascular risk factors 3

For splanchnic vein thrombosis specifically 5:

• Low molecular weight heparin followed by long-term oral anticoagulation (INR 2.0-3.0) 5
• Hydroxyurea to restore platelet count to 400 × 10⁹/L as rapidly as possible 5
• Consider intensive interventions (TIPS, angioplasty, surgical shunts) for severe cases 5

For patients with previous major bleeding 5:

• Avoid aspirin 5
• Consider interferon alfa to reduce thrombocytosis instead of hydroxyurea 5

For pregnancy in high-risk patients 5:

• Low molecular weight heparin throughout pregnancy (stop aspirin if bleeding occurs) 5
• Consider interferon alfa if platelet count ≥1,500 × 10⁹/L 5

Low-Risk Patients

Observation with cardiovascular risk factor modification may be appropriate for younger patients without thrombosis history and platelet counts <1,500 × 10⁹/L 3.

Management of Secondary Thrombocytosis

Treat the underlying condition 2, 1:

• Iron replacement for iron deficiency 2
• Anti-inflammatory therapy for inflammatory conditions 2
• Treatment of underlying malignancy 2
• Management of infection 2

Secondary thrombocytosis typically does not require platelet-lowering therapy or antiplatelet agents unless there are independent indications 6, 3.